SynthesisHormone research in paediatrics2024
The Effect of GnRHa Treatment on Body Mass Index in Central Precocious Puberty: A Systematic Review and Meta-Analysis.
Synthesis in Hormone research in paediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Efficacy of combined gonadotropin-releasing hormone analogue and growth hormone therapy in girls with central precocious puberty: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.Advances in therapy · 2024Trial
- Pubertal Triptorelin Exposure Alters Hypothalamic Reproductive-Metabolic Integration in a Sex-Specific Manner.Biology · 2026Article
- Menarche timing after GnRHa treatment in cases of central precocious puberty or early and fast puberty.European journal of pediatrics · 2026Observational
- Case Report: Sequential treatment of growth hormone deficiency and central precocious puberty in a girl withFrontiers in pediatrics · 2026Article
- Comparative efficacy of quarterly vs. monthly triptorelin in Chinese girls with central precocious puberty: a 12-month observational study.Frontiers in pediatrics · 2026Article
- Central precocious puberty in boys; diagnosis, treatment and follow-up: a nation-wide study.Endocrine · 2025Article
- Trend in body mass index during childhood in 460 girls with idiopathic central precocious puberty.Endocrine connections · 2025Article
- The Effect of GnRH Analogs on Body Mass Index in Girls with Central Precocious Puberty: A Single-Center Retrospective Study with a Literature Review.Children (Basel, Switzerland) · 2025Article
- Impact of dietary patterns on body weight in girls with central precocious puberty treated with leuprolide during the COVID-19 pandemic.Frontiers in pediatrics · 2025Article
- A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, numerous studies have addressed the long-term effects of treatment with gonadotropin-releasing hormone analog (GnRHa) in patients with central precocious puberty (CPP). However, the effects of GnRHa treatment on body mass index (BMI) in patients with CPP remain controversial.
objectiveThis systematic review and meta-analysis aimed to evaluate the association between GnRHa treatment and BMI in patients with CPP.
methodsA systematic search of databases, PubMed, EMBASE, and Web of Science published before August 2021 identified relevant studies. The overall effect analysis was performed using STATA version statistical software 15.0.
resultsThe study included a total of 28 studies. At the end of GnRHa treatment, the BMI-standard deviation score (BMI-SDS) was greater than baseline BMI-SDS (weighted mean difference (WMD) = 0.14, 95% CI: 0.04-0.23; p = 0.004), especially in girls with CPP (WMD = 0.15, 95% CI: 0.05-0.25; p = 0.005) and in patients with normal weight (WMD = 0.34, 95% CI: 0.19-0.48, p < 0.001). After reaching adult height, BMI-SDS returned to baseline, suggesting that the effect of GnRHa treatment on BMI would disappear as the child grew (WMD = -0.03, 95% CI: -0.39 to 0.32; p = 0.815).
conclusionFor patients with CPP, while treatment with GnRHa may increase the BMI in the short term after treatment, the BMI is likely to return to normal when the patients reach adult height.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.